News Image

Why NYSE:JNJ qualifies as a good dividend investing stock.

By Mill Chart

Last update: Dec 19, 2023

Take a closer look at JOHNSON & JOHNSON (NYSE:JNJ), a stock of interest to dividend investors uncovered by our stock screener. NYSE:JNJ excels in fundamentals and provides a decent dividend, all while maintaining a reasonable valuation. Let's break it down further.

Dividend Assessment of NYSE:JNJ

ChartMill employs its own Dividend Rating system for all stocks. This score, on a scale of 0 to 10, is determined by evaluating different dividend factors, such as yield, historical performance, dividend growth, and sustainability. NYSE:JNJ has been assigned a 7 for dividend:

  • Compared to an average industry Dividend Yield of 4.63, JNJ pays a better dividend. On top of this JNJ pays more dividend than 93.10% of the companies listed in the same industry.
  • JNJ's Dividend Yield is a higher than the S&P500 average which is at 2.45.
  • On average, the dividend of JNJ grows each year by 9.96%, which is quite nice.
  • JNJ has been paying a dividend for at least 10 years, so it has a reliable track record.
  • JNJ has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
  • 34.25% of the earnings are spent on dividend by JNJ. This is a low number and sustainable payout ratio.

Understanding NYSE:JNJ's Health Score

ChartMill utilizes a Health Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of liquidity and solvency ratios, both in absolute terms and in comparison to industry peers. NYSE:JNJ has earned a 7 out of 10:

  • An Altman-Z score of 4.75 indicates that JNJ is not in any danger for bankruptcy at the moment.
  • JNJ's Altman-Z score of 4.75 is amongst the best of the industry. JNJ outperforms 81.28% of its industry peers.
  • JNJ has a debt to FCF ratio of 1.90. This is a very positive value and a sign of high solvency as it would only need 1.90 years to pay back of all of its debts.
  • The Debt to FCF ratio of JNJ (1.90) is better than 91.63% of its industry peers.
  • JNJ has a Debt/Equity ratio of 0.39. This is a healthy value indicating a solid balance between debt and equity.
  • Although JNJ does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
  • JNJ does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.

Understanding NYSE:JNJ's Profitability

Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NYSE:JNJ has achieved a 9:

  • JNJ has a better Return On Assets (20.85%) than 97.04% of its industry peers.
  • JNJ has a better Return On Equity (48.61%) than 96.06% of its industry peers.
  • With an excellent Return On Invested Capital value of 17.66%, JNJ belongs to the best of the industry, outperforming 93.60% of the companies in the same industry.
  • The 3 year average ROIC (15.62%) for JNJ is below the current ROIC(17.66%), indicating increased profibility in the last year.
  • With an excellent Profit Margin value of 39.58%, JNJ belongs to the best of the industry, outperforming 98.03% of the companies in the same industry.
  • JNJ's Profit Margin has improved in the last couple of years.
  • JNJ's Operating Margin of 28.66% is amongst the best of the industry. JNJ outperforms 94.58% of its industry peers.
  • In the last couple of years the Operating Margin of JNJ has grown nicely.
  • Looking at the Gross Margin, with a value of 68.86%, JNJ is in the better half of the industry, outperforming 75.37% of the companies in the same industry.

Every day, new Best Dividend stocks can be found on ChartMill in our Best Dividend screener.

Our latest full fundamental report of JNJ contains the most current fundamental analsysis.

Disclaimer

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.

Back

JOHNSON & JOHNSON

NYSE:JNJ (4/23/2024, 7:08:20 PM)

After market: 149.2 -0.36 (-0.24%)

149.56

+0.44 (+0.3%)

JNJ News

News Image6 hours ago - InvestorPlaceWarning! These 3 Blue-Chip Stocks Will Have You Seeing Red

These stocks are underwater right now and likely to remain so as the companies behind them manage serious problems.

News Image13 hours ago - Investor's Business DailyNo. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Win

The company is establishing its line-up of drugs behind bread-and-butter med Ingrezza.

News Image13 hours ago - Zacks Investment Research4 Stocks to Watch on Their Recent Dividend Hikes

Stocks like KB Home (KBH), Interactive Brokers Group, Inc. (IBKR), QUALCOMM Incorporated (QCOM) and Johnson & Johnson (JNJ) recently hiked dividends.

News Imagea day ago - Johnson & JohnsonJohnson & Johnson to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC)
News Imagea day ago - Brodsky & Smith LLCBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Macatawa Bank Corporation (Nasdaq - MCBC), Shockwave Medical, Inc. (Nasdaq – SWAV), Apartment Income REIT Corp. (NYSE - AIRC), Model N, Inc. (NYSE – MODN)
News Imagea day ago - InvestorPlace3 Dividend Stocks to Buy Now for Lifelong Income

Here are three dividend stocks to buy now offering stability, growth, and lifelong income in the pharmaceutical and tobacco industries.

News Image2 days ago - InvestorPlace3 Dividend Kings Down 11% You’ll Regret Not Buying on the Dip

These dividend stocks have proved time and again why they're the cream of the crop and will rise to the top once more.

News Image2 days ago - InvestorPlace5 Crash-Proof Stocks to Buy Immediately

We may not be headed to a full-blown crisis, but savvy investors should protect their portfolios now with these crash-proof stocks.

News Image2 days ago - InvezzBest biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX

Biotech stocks are having a relatively strong year as investors focus on the growing M&A in the healthcare space. Johnson & Johnson is acquiring Shockwave Medical while Novo Nordisk is buying Catalent, a CDMO organization. Pfizer acquired Seagen in 2023 while Merck bought Harpoon Therapeutics. So, here are some of the top biotech stocks to […]

News Image3 days ago - BloombergJ&J, Kenvue Told to Pay $45 Million to Baby Powder User’s Family

Johnson & Johnson and Kenvue Inc. were ordered to pay $45 million to the family of an Illinois woman who blamed the companies’ baby powders for giving her a fatal cancer in what was the first verdict against the J&J spinoff in a decade-long litigation over the product.

News Image4 days ago - InvestorPlaceInvesting for the Long-Term: 3 Stocks With Proven Track Records

As uncertainty in the global economy and geopolitical climate abounds, investors should focus on stocks with proven track records.

News Image4 days ago - ForbesCourt Orders Johnson & Johnson And Kenvue To Pay $45 Million In Talcum Baby Powder Lawsuit

Friday’s ruling in Illinois came a day after a judge in Florida rejected similar claims.

JNJ Links
Follow us for more